Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Clim8 is a financial technology company that aims to move billions of pounds of investment into sectors such as clean energy, clean technology, sustainable food, smart mobility, and recycling. It is authorised by the Financial Conduct Authority (FCA). The company quotes United Nations data arguing that the world needs to invest $2.4 trillion every year into clean energy, from now until 2035, to meet climate change targets. Clim8 aims to capitalise on this objective through its app. The company has raised £1.9 million in seed funding across two rounds, in December 2019 and April 2020, respectively. It also overachieved its first Crowdcube campaign by over 300%. The company will use the investment to continue onboarding its waiting list of over 10,000 and grow its business across different verticals.
days to go:
Expired
investment:
£2,348,974
Investly are an invoice financing marketplace that help European businesses finance their invoices by bringing them the best price from multiple providers. In 2 years they have financed just over £18m worth of invoices.
days to go:
Expired
investment:
£679,085
Verado is a data-driven and scalable proprietary platform that aims to eradicate counterfeits within the watch & jewelry industry. It enables private sellers to sell their luxury watches autonomously online. Verado analyzes thousands of similar items across the internet and gives the fairest price for both buyers and sellers. By adding verification, authentication and financial escrow, Verado is solving a basic problem associated with buying and selling fine jewelry. In a market with zero transparency, Verado is able to provide a community for collectors, sellers, and buyers. The platform has the security and personality of old school selling with the reach and speed of an online platform. The company has achieved €400,000+ sales and 10,000 cellular listings onto the platform. Verado has been featured in many publications like watchuseek, Forbes, and Buzzfeed. With the proceeds, the company is planning to build awareness and build upon its growing community.
days to go:
Expired
investment:
£37,270
A mobile-based credit card created by a team consisting of members from American Express, Capital One, Zopa, LendingClub and Trussle. Fea are raising funds to develop the app and aim to launch their product in 2019. The initial offering will be a prepaid card, with a full credit card following shortly after. The company is also in the process of acquiring FCA authorisation.
The company aims to generate revenue via a fixed monthly subscription, with no other fees. The pricing will be set to the customer's credit limit, divided by 100. For example, if the customer’s credit limit is £1000, their monthly subscription cost will be £10.
days to go:
Expired
investment:
£102,230
Plant-based diets, health and fitness programmes for those interested in veganism to improve their health and wellbeing. Skinny Bitch's book has sold more than 1.1m copies and is available in 6 languages. Readers of the book include celebrities such as Eva Longoria and Jessica Alba. Ellen DeGeneres has stated that the Skinny Bitch book is the reason she became vegan.
The company is now expanding their brand further by offering their content through online guides and blogs. Skinny Bitch is also intending to generate revenue via vegan supplements produced in the US to be sold through their website and third party e-commerce channels.
days to go:
Expired
investment:
£75,810
Appital is an emerging financial market platform that will use digital profiling, unique algorithms and notifications to connect institutional demand and supply. With Appital, corporate and institutional companies within the equity capital markets space will have the opportunity to exchange illiquid equity without an investment bank or broker. Appital will also remove the dependence on email and phone, thereby ensuring efficiency and accessibility. The company is raising fund to built the Appital software, achieve FCA regulation, generate marketing material and gain contracts with partner settlement and KYC providers. Furthermore, the company will enhance the functionality of the software by leveraging its network to other products such as primary debt and primary equity deal flow.
days to go:
Expired
investment:
£349,060
